Exclusive Summary

• The originator's patent has long expired with zero IP barriers, allowing overseas distributors to rapidly register and capture generic market share, especially in emerging markets.
• Targeting a massive global pool of over 64 million patients with schizophrenia and bipolar disorder, this chronic essential medication guarantees continuous and stable long-term recurring demand.
• Available in core 50mg, 100mg, and 200mg strengths to cover both clinical titration and maintenance needs, offering supreme price competitiveness for government tenders leveraging China's manufacturing cost advantages.